The Daily

Manufacturing time is still the quiet bottleneck of CAR-T in myeloma, and this Transplantation and Cellular Therapy paper goes straight at the uncomfortable question: what does aggressive bridging do to outcomes after idecabtagene vicleucel (ide-cel)? The team looked at patients who received intensive, cyclophosphamide-containing multi-agent bridging therapy during the wait. The key point isn’t that bridging is “bad” — it’s that intensity may be a proxy for biology (fast disease) and may also add its own toxicity and immune disruption. Practically, it reinforces a workflow implication: if a patient needs heavy multi-agent chemo to stay afloat, the center should treat it as a red flag and tighten the timeline (apheresis-to-infusion logistics, inpatient slot planning, infection prophylaxis). It also nudges the field toward earlier referral and toward bridging strategies that preserve T-cell fitness rather than just debulking at any cost. Next step is obvious: stratify by disease aggressiveness and prior exposure to alkylators, then prospectively compare bridging “profiles” rather than hand-waving with retrospective labels.

ICANS has become the default mental model for “CAR-T neurotox,” but this Frontiers in Immunology case report is a useful reminder that the phenotype is broader. The authors describe a patient after CD19-directed CAR-T who developed a movement and neurocognitive treatment-emergent adverse event (a syndrome previously described mainly with BCMA-directed products in myeloma). The clinical implication is operational: centers should maintain a differential diagnosis that includes non-ICANS patterns, especially when timing, symptoms, or imaging don’t fit the usual CRS→ICANS arc. It also matters for patient counseling — “neurotoxicity” isn’t one thing, and recovery trajectories differ. Finally, it’s a research nudge: we need shared definitions (and ideally biomarkers) for these non-ICANS syndromes so they don’t get lost as “atypical delirium” in retrospective registries.

Microsoft is making a pretty explicit bet that “Copilot” is moving from chat UI to agent orchestration, and the announcement is notable for how directly it names the model mix. In their Microsoft 365 blog post, Microsoft says it has worked with Anthropic to bring the technology that powers Claude Cowork into Microsoft 365 Copilot and to make Claude Sonnet models available to Copilot users. That is strategically important because Copilot has historically been read as “OpenAI-first,” and this looks like a deliberate hedge (and a leverage move) in a market where reliability, governance, and cost curves matter more than raw benchmark wins. The real product question is whether this translates into repeatable agent behavior inside enterprise guardrails — permissions, audit logs, and “who did what” provenance. If it works, it pushes the center of gravity toward suites where the agent can touch calendar, docs, mail, and files without brittle integrations. The next step to watch is pricing and quota policy: agents are only “real” when they’re cheap enough to run all day without forcing users into micro-optimizing prompts.

After years of platforms arguing that age verification is either impossible or privacy-toxic, the compliance landscape is shifting. This Reuters-syndicated report (via U.S. News) frames it as a two-sided pressure: a wave of kids’ online safety laws on one side and rapidly improving (and cheaper) age-estimation/verification tooling on the other. The hard part is not the ML — it’s the product design: doing age gates without turning the internet into a document-upload kiosk, and without storing sensitive identifiers in ways that create new breach risk. There’s also a geopolitical angle: different jurisdictions will set different thresholds for “reasonable assurance,” which forces global platforms into a patchwork of regional flows. The next step is likely a standardization push around privacy-preserving age proof (think tokenized attestations), because the alternative is each app reinventing identity infrastructure badly.

JetBrains is trying to make “agentic coding” feel like a first-class developer workflow rather than a browser tab. The Junie CLI beta is positioned as LLM-agnostic — meaning it’s designed to work across providers, including the option to use your own API keys, instead of being locked to a single model vendor. That matters because serious teams will optimize across cost, latency, and compliance, and they don’t want their tooling strategy held hostage by one roadmap. Terminal-first is also a good choice: it fits CI/CD, Git hooks, and reproducible automation in ways that IDE-only assistants often don’t. The next step to evaluate is the boring-but-critical stuff: how Junie handles permissions (file writes, command execution), how it explains diffs, and whether it can be made safe enough for production repos without turning into a constant “are you sure?” machine.

The FDA has issued draft guidance intended to make it easier for developers to bring biosimilars of complex biologic medicines to market — the kind of molecules that dominate spending in cancer and autoimmune disease. The headline sounds procedural, but the stakes are concrete: if the agency can credibly reduce unnecessary comparative testing while maintaining confidence in similarity, timelines and development costs come down, and competition arrives earlier. That would directly pressure pricing for blockbuster biologics, but it also changes portfolio strategy: more companies can afford to enter categories that were previously reserved for the few with massive manufacturing and clinical budgets. The hard detail to watch is what the FDA accepts as “enough” evidence for high-dimensional similarity (analytics, PK/PD, immunogenicity) and where it still insists on clinical endpoints. The next step is predictable: industry comments will try to lock in certainty, while originators will push to keep the evidentiary bar high in the name of safety. If the final guidance lands close to the draft, 2026–2028 could see a materially denser biosimilar pipeline for the most expensive immune and oncology biologics.

Italian pharma Alfasigma is paying GSK to take rights to an itching treatment that’s still sitting in front of the FDA — a structure that basically prices in regulatory uncertainty. Fierce Biotech reports a deal headline of up to $690 million, with a large upfront component and additional milestones if the drug clears the agency on schedule. The interesting strategic angle is the timing: buying pre-approval compresses the wait-to-launch window, but it also concentrates risk into a single binary event. It’s also a reminder that symptom-focused, specialty-liver or cholestatic disease assets can still attract real money when they have clear patient demand and prescriber pathways. Next step: if the FDA decision lands cleanly, Alfasigma inherits not just a product but an operational sprint — manufacturing readiness, payer strategy, and the “first 90 days” commercial muscle that determines whether a niche drug becomes a franchise or a footnote.

GLP-1 is no longer a category; it’s a platform war, and amylin analogs are one of the most credible “next levers” for additional weight loss and tolerability. Fierce Biotech reports that AbbVie’s amylin program — the one tied to a $350 million deal — delivered almost 10% weight loss after 12 weeks in early data. The hard detail here is the timepoint: 12-week signals matter because they’re early enough to shape dose selection, but they can also flatter drugs that later plateau. Strategically, AbbVie is trying to buy its way into a market where incumbents (Novo, Lilly) have manufacturing scale and prescriber mindshare that are difficult to replicate. The next step is whether the safety/tolerability profile supports longer duration dosing — nausea and discontinuation rates will decide whether “nearly 10% at 12 weeks” becomes “meaningfully differentiated at 52 weeks.” If AbbVie can pair an amylin with a GLP-1 (or a triple agonist), it’s not just about obesity: it’s about owning cardiometabolic risk reduction as a durable franchise.

Die Stadt Wien hat den Abschluss der 31. Saison des Wiener Eistraums kommuniziert — und macht dabei gleich den Blick nach vorn sehr konkret. In der Aussendung steht bereits der Zeitraum für die nächste Ausgabe: 22. Jänner bis 7. März 2027 (also wieder ein ziemlich langes Winterfenster). Das ist mehr als ein PR-Nachtrag: für Familien und Schulen ist der Eistraum ein planbares „Fix-Event“, und die frühe Termin-Kommunikation hilft bei der Jahresplanung. Interessant ist außerdem, dass solche Großformate inzwischen wie Infrastruktur behandelt werden: nicht nur „Event“, sondern wiederkehrender Stadtbaustein mit Erwartungsmanagement. Wenn du dieses Jahr selten dort warst: nimm dir nächstes Jahr ein Zeitfenster unter der Woche – das ist der Unterschied zwischen „nett“ und „wirklich entspannt“.

MeinBezirk berichtet über die Eröffnung eines zweiten Cocore-Standorts in Wien — diesmal in der Innenstadt, mit Fokus auf Kampanien-Feeling. Solche Expansionen sind ein gutes Signal: entweder läuft das erste Lokal stabil genug für ein zweites, oder das Konzept trifft einen Nerv in der Stadt (oder beides). Für Wien ist das kulinarisch kein exotischer Move, sondern Teil einer klaren Linie: authentischere Regionalität statt „italienisch als Genre“. Als Leser ist der Mehrwert vor allem praktisch: mehr Verfügbarkeit, kürzere Wege, und meist auch ein „zweiter Anlauf“ beim Konzept (Karte, Service, Reservierungssystem) mit gelerntem Feedback. Next step: schauen, ob es eher Aperitivo/Bar-Fokus wird oder ein klassischer Dinner-Spot — das entscheidet, ob es ein Stammplatz oder ein „hin und wieder“-Lokal wird.

Ein solides Familien-Utility-Stück: die Wiener Abfallberatung bewirbt für 2026 wieder „Bunte Tage in den Osterferien“ als Teil des Osterferienspiels. Laut Ankündigung können Kinder von 7 bis 10 Jahren kostenlos mitmachen — das ist genau die Art Angebot, die den Ferienkalender rettet, wenn man nicht jeden Tag „großen Ausflug“ spielen will. Inhaltlich geht es (erwartbar) um Umwelt/Abfall, aber der eigentliche Wert ist der Rahmen: betreut, strukturiert, und meist mit einer Mischung aus Basteln/Experimentieren statt Frontalunterricht. Wichtig in der Praxis: solche Slots sind oft schneller voll als man glaubt, weil „kostenlos + Ferien“ eine starke Kombination ist. Next step: früh anmelden und parallel einen Plan B behalten, falls die Wunschtermine weg sind.

Vienna Inside hat einen kompakten Überblick über die Ostermärkte 2026 in Wien, inklusive Terminen und Locations, die man sonst leicht verpasst. Ein Detail, das heraussticht: die Kalvarienberggasse/St.-Bartholomäus-Platz werden 19. März bis 5. April zum Oster-Setup „für alle Generationen“ — also genau in dem Zeitfenster, in dem Wien plötzlich wieder draußen stattfindet. Für Kinder ist der Nutzwert banal, aber real: Märkte sind planbare Nachmittage mit Bewegung, Snacks, und (meist) kleinen Bastel-/Mitmachstationen. Für Eltern ist es ein „low commitment“-Ausflug: man kann nach 45 Minuten gehen, ohne dass es sich wie Abbruch anfühlt. Next step: unter der Woche hingehen, wenn möglich — am Wochenende kippt die Stimmung je nach Wetter schnell in „zu voll“.

If you want a Venice trip that isn’t pure crowd-management, late March is the sweet spot — and the Pinault Collection is giving it a clean reason. Curatory Magazine highlights that four solo exhibitions open in Venice on 29 March 2026 across the Pinault venues (Punta della Dogana / Palazzo Grassi ecosystem). The practical value is calendar structure: you can build a two-day itinerary around one strong contemporary-art spine, then fill the rest with the usual Venice pleasures (walks, cicchetti, islands) without feeling like you “missed” the main thing. It’s also a good counterweight to the Biennale hype cycle: you get serious shows, but not the full May/June intensity. Next step: book accommodation now if you’re targeting the last weekend of March — Venice pricing can jump on any art-driven micro-peak, even outside high summer.

PugliaPress kündigt für Dienstag, 10. März 2026 das regionale „Festival Agrichef“ in Castellaneta (Taranto) an, Start laut Artikel um 10 Uhr an einer Hotelfachschule. Für Travel-Planung ist das weniger „hinfahren wegen genau dieses Events“, sondern ein Signal für die Saison: wenn solche Formate laufen, ist die Region aus dem Wintermodus raus. Inhaltlich geht es um lokale Produkte und Koch-Handwerk (Turismo Verde / Agriturismo-Umfeld) — genau die Art kulinarischer Kultur, die Puglia von vielen anderen Strandregionen unterscheidet. Wenn du im Frühjahr in der Gegend bist, lohnt sich generell der Fokus auf Landküche und Märkte, nicht nur Küste. Next step: solche Events sind oft in italienischer Info-Lage etwas unübersichtlich; im Zweifel die Location direkt kontaktieren oder lokale Tourismus-Seiten gegenchecken, bevor man einen Tagesausflug darauf baut.

NBA.com’s Starting 5 is basically the cleanest way to see what the league thinks mattered last night — and the March 9 edition reads like the season’s “second half identity” locking in. The Spurs continuing to roll is not just a fun streak story; it changes who can realistically climb (or fall) in the West as schedule difficulty bites. The piece also flags Jayson Tatum’s impact as he keeps stacking strong nights after his return, which matters because Boston’s ceiling is still the Eastern Conference reference point. What I like here is the framing: it’s less “box score,” more the connective tissue that turns random March games into playoff leverage. Next step: watch for rest-disadvantage games and back-to-backs this week — that’s where seeding gets quietly stolen, especially for teams already thin on depth.

The scoreline is brutal: Orlando beat Milwaukee 130–91, and the context makes it even more instructive. Yahoo’s recap frames it as a back-to-back problem for the Bucks, compounded by absences (including Giannis in this write-up’s framing). March blowouts aren’t always “true talent” — they’re often schedule + bodies + motivation. But they still matter, because point-differential swings and tiebreakers can become real, and because heavy minutes in March tend to show up as dead legs in late April. Next step: if you’re tracking contenders, watch which teams can still win ugly on the second night of a back-to-back — that’s a better playoff proxy than highlight games.